Patient Journey Market Research in Singapore: What Healthcare Brands Generally Miss
Assembled is a market research agency in Singapore with 600+ projects completed across Southeast Asia since 2016, a 100,000-member proprietary panel, and publications in MRS Research Live and ESOMAR Research World. This patient journey mapping in Singapore healthcare analysis draws on patterns from healthcare research projects moderated by founder Felicia Hu, who scopes, moderates, analyses, and presents every project herself. In Singapore’s high-context culture, a participant who says “can consider” is saying no. Felicia, a bilingual moderator in English and Mandarin with fluency in Hokkien, Cantonese, and Singlish, was recently quoted in the South China Morning Post on Singapore consumer healthcare decisions.
Patient Journey Market Research in Singapore: What Healthcare Brands Generally Miss
Healthcare brands map patient journeys on whiteboards. Neat arrows connecting diagnosis to treatment to adherence to outcome. The reality looks nothing like the diagram.
Singapore patients navigate a system shaped by subsidies, family dynamics, cultural beliefs about illness, and institutional complexity that journey maps rarely capture. According to MOH's healthcare financing framework, Singapore operates a unique 3M system — Medisave, MediShield Life, and Medifund — that shapes every healthcare decision before clinical considerations even enter the picture. Agency for Integrated Care data shows subsidy utilization patterns vary dramatically by patient segment in ways that are not visible from clinical records alone. SingStat population data shows Singapore's resident population aged 65 and above will exceed 25% by 2030, making the intersection of aging demographics and complex healthcare navigation one of the most urgent research challenges in Singapore's consumer health market. The Health Promotion Board's chronic disease management resources describe the intended patient pathway; our research maps the actual one.
The patient who appears on your whiteboard journey map is making rational, system-optimizing decisions. But the system they are optimizing is not the one your brand designed for. This is the healthcare equivalent of the say-do gap: patients tell doctors they want the best treatment, while their actual behavior optimizes for financial sustainability, family consensus, and system navigation efficiency.
What Singapore Patient Journey Research Actually Finds
The Subsidy Calculation Comes First
Before considering treatment efficacy, side effects, or brand preference, Singapore patients calculate subsidy eligibility. Which hospitals are subsidized? What is the difference between B2 and C ward pricing? Will this treatment deplete Medisave balance needed for anticipated future conditions?
For chronic conditions requiring ongoing treatment, the financial calculation becomes the primary filter — often eliminating treatment options before the patient reaches the point of asking whether they are clinically appropriate. A patient might choose a less optimal treatment pathway because it preserves Medisave for anticipated future needs. If your patient journey map does not include a financial decision node before the treatment decision node, it is incomplete by design.
The Referral Maze
Singapore's tiered system — polyclinics to specialists to tertiary hospitals — creates navigation challenges that affect care-seeking behavior in ways that do not appear in official pathway descriptions. SingHealth's patient care pathways describe the intended flow. Actual patient behavior shows a more complex picture: patients learn the system through experience, word-of-mouth, and trial-and-error, then adapt their navigation strategies accordingly.
Some patients bypass polyclinics entirely despite higher costs, having learned that direct specialist access produces faster diagnosis. Others game the referral system specifically to access subsidy tiers. These navigation strategies are invisible to brands designing patient support programmes around the official pathway. They are also the single most important insight for understanding where your brand fits in the patient's actual decision sequence.
The Family Decision Unit
Healthcare decisions in Singapore rarely involve the patient alone. Adult children research options for aging parents. Spouses attend consultations and sometimes speak for patients. Family WhatsApp groups debate treatment choices, synthesize advice from relatives with medical backgrounds, and reach collective decisions that the patient then presents to their doctor as a personal choice.
Our caregiver research found that for chronic conditions in older patients, the actual decision-maker is often the filial daughter managing her father's care — not the father himself. Her information-seeking behavior, her fear hierarchy, and her willingness to pay for non-subsidized options are the relevant variables. Yet most patient journey research interviews the patient alone, missing the primary decision influencer entirely.
The Parallel Track
Many Singapore patients maintain parallel healthcare relationships: Western medicine through the public or private system, plus TCM practitioners, plus supplements, plus temple visits for serious diagnoses. These tracks rarely communicate with each other. Patients often do not disclose parallel treatments to their primary physicians, fearing judgment or perceived criticism of their choices.
The actual health behavior is broader than what appears in any single medical record, and broader than what patients will volunteer in direct questioning. Understanding these parallel tracks requires the kind of non-judgmental probing that our HCP research methods are designed to surface — asking "what else are you doing to support your health?" rather than "are you taking anything your doctor doesn't know about?"
Four Patient Segments by System Navigation Style
| Segment | Share | Behavior Pattern |
|---|---|---|
| System Navigators | 20–25% | Have learned to work the system. Know which hospitals offer better subsidies, how to expedite referrals. High health literacy. Most likely to adopt new treatment pathways if the system logic supports it. |
| Passive Compliers | 30–35% | Follow whatever the polyclinic doctor recommends. Trust the system. May miss opportunities for better care pathways because they do not know to ask. Highly influence-able by healthcare brand education. |
| Private Defaulters | 15–20% | Default to private care regardless of subsidy implications. Value speed and doctor relationships over cost optimization. Accessible through private specialist channel but resistant to public system recommendations. |
| The Overwhelmed | 20–25% | Find the system confusing. May delay care or accept suboptimal pathways. Often elderly patients without family advocates navigating complexity alone. |
The Decision Factor Gap
What patients say drives their healthcare decisions diverges consistently from what actually influences their behavior. This mirrors the chronic disease management research finding that adherence determinants — what actually drives whether a patient takes their medication — are systematically understated in direct research questions.
| Decision Factor | Stated Importance | Actual Importance |
|---|---|---|
| Doctor's recommendation | Very High | High (but filtered through subsidy and family) |
| Subsidy and Medisave eligibility | Moderate | Very High (primary filter) |
| Family member input | Moderate | Very High (often the actual decision) |
| Treatment efficacy data | Very High | Moderate (if subsidy filter passed) |
| Wait times and convenience | Moderate | High |
| Word-of-mouth about specific doctors | Moderate | High (especially for specialist selection) |
Research Approaches That Actually Work
Three practices differentiate healthcare research that produces actionable insight from research that maps only the official patient pathway.
First, interview the family, not just the patient. For chronic conditions affecting older patients, interview adult children separately. Their perspective on decision-making often differs substantially from the patient's account and may be more accurate about actual decision sequence. Our caregiver research methodology was developed specifically for this dual-interview purpose.
Second, map the parallel tracks. Ask about TCM, supplements, religious practices, and community advice networks. Frame questions without judgment: "What else are you doing to support your health?" consistently produces richer data than "Are you taking anything your doctor doesn't know about?" The framing signals permission to share, not interrogation.
Third, trace the financial journey. Walk through the actual financial calculations: what did Medisave cover, what came out of pocket, what is the ongoing cost burden forecast. Financial stress affects adherence and care-seeking in ways patients do not articulate directly — but which are plainly visible when you trace the transaction history alongside the treatment history. This approach is documented in our mental health services research, where the financial journey is particularly complex given the limited subsidization of mental health services relative to physical health.
The sensitive skin market research we conduct shows a parallel dynamic: consumers with chronic skin conditions navigate similarly fragmented systems of dermatologists, pharmacies, and self-treatment. The navigation logic — optimize cost, reduce uncertainty, manage the parallel track — is structurally identical to healthcare navigation, which is why methodologies developed in one domain often transfer to the other.
Frequently asked questions
How does the subsidy system shape patient journey research in Singapore?
If your patient journey map does not include a financial decision node before the treatment decision node, it is incomplete. For most Singapore patients, the subsidy calculation happens before they consider treatment options. What happens to your brand when it is not on the subsidized list? Patients who would benefit from your product may never reach the point of considering it because the financial filter eliminated the pathway first. Research that maps the full financial decision sequence — including Medisave planning, subsidy tier comparison, and out-of-pocket ceiling setting — produces dramatically different strategic implications than research that starts at the point of clinical choice.
What navigation barriers prevent patients from reaching optimal care pathways?
Three categories of barriers appear consistently in our research. Information barriers: patients do not know which pathways are available, or which system navigations would improve their care. Complexity barriers: the referral and subsidy system is genuinely confusing, and patients without family advocates or high health literacy make suboptimal pathway choices by default. Inertia barriers: patients who have established a care relationship, even a suboptimal one, resist disruption — the psychological cost of changing doctors or systems outweighs the clinical benefit of a better pathway for most patients most of the time. Each barrier calls for different intervention design.
How do products interact with the 3M system in ways that shape patient decisions?
Products that are Medisave-claimable have a structural advantage that goes beyond the direct subsidy benefit: they signal system endorsement, which increases doctor recommendation confidence and patient trust simultaneously. Products that are not claimable face a persistent out-of-pocket cost comparison that clinical arguments alone rarely overcome for price-sensitive segments. Understanding exactly where your product sits in the 3M calculation for each patient segment — and what the decision looks like from the patient's financial perspective — is the most underinvested research question in healthcare brand strategy in Singapore.
When should healthcare brands interview caregivers separately from patients?
For any condition affecting patients over 60, or any chronic condition with significant functional impact on daily life, caregiver research should be conducted alongside patient research rather than as an afterthought. The caregiver's information-seeking behavior, fear hierarchy, and willingness to pay for non-subsidized options are often the variables that actually determine treatment choice. Our caregiver research found that for conditions like diabetes, dementia, and cancer, the primary carer initiates the majority of treatment pathway changes — yet most patient journey research treats them as peripheral participants rather than the central decision-making unit they often are.
Observations in this post draw on patterns from Assembled's healthcare research projects in Singapore, including in-depth interviews and focus group discussions with patients, caregivers, and healthcare professionals. Secondary data from Ministry of Health healthcare financing data, Agency for Integrated Care service utilization reports, and SingStat demographic data. For research enquiries, contact felicia@assembled.sg., in-depth interviews, focus group discussions, our case studies
Mapping the real patient journey, not the one in the textbook
Subsidies, family dynamics, and the 3M system create patient pathways your clinical framework does not capture. We recruit patients who have navigated your specific condition.
Request a quote →
